Three-year clinical outcomes of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient-level pooled analysis of NeoVas trials.
Xiao-Zeng WangYaling HanGuosheng FuBo XuYu Jie ZhouXi SuHuiliang LiuZheng ZhangBo YuLing TaoQun ZhengLang LiKai XuYa-Ling Hannull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023)
The extended outcomes of the NeoVas objective performance criterion trial demonstrated a promising 3-year efficacy and safety of the NeoVas BRS in low-risk patients with low complexity in terms of lesions and comorbidities.